Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Clin Cancer Res. 2018 Dec 26;25(9):2755–2768. doi: 10.1158/1078-0432.CCR-18-3230

Figure 2. MiR-338-5p and miR-421 abrogates oncogenic properties of SPINK1-positive prostate cancer cells.

Figure 2

(A) Cell proliferation assay using 22RV1-miR-338-5p, 22RV1-miR-421 and 22RV1-CTL cells at the indicated time points.

(B) Boyden chamber Matrigel invasion assay using same cells as in (A). Representative fields with invaded cells are shown in the inset (n=3 biologically independent samples; data represent mean ± SEM).

(C) Soft agar assay for anchorage-independent growth using same cells as in (A). Representative soft agar colonies are shown in the inset (n=3 biologically independent samples; data represent mean ± SEM).

(D) Foci formation assay using same cells as in (A). Representative images depicting foci are shown in the inset (n=3 biologically independent samples; data represent mean ± SEM).

(E) Mean tumor growth in NOD/SCID mice (n=8) subcutaneously implanted with stable 22RV1-miR-338-5p and 22RV1-CTL cells.

(F) Same as (E), except stable 22RV1-miR-421 cells were implanted.

(G) Same as (E and F), except genomic DNA extracted from the lung and bone marrow of the xenografted mice.

Data represent mean ± SEM. *P≤ 0.05 and **P≤ 0.005 using two-tailed unpaired Student's t test.